Compare Stocks

Date Range: 

 VBI VaccinesBicycle TherapeuticsVeruChimerixChinook Therapeutics
SymbolNASDAQ:VBIVNASDAQ:BCYCNASDAQ:VERUNASDAQ:CMRXNASDAQ:KDNY
Price Information
Current Price$2.78$31.75$7.81$8.15$16.26
52 Week RangeBuyBuyBuyBuyBuy
MarketRank™
Overall Score1.51.31.41.71.4
Analysis Score3.63.53.54.53.5
Community Score3.22.42.92.42.8
Dividend Score0.00.00.00.00.0
Ownership Score0.80.80.01.70.0
Earnings & Valuation Score0.00.00.60.00.6
Analyst Ratings
Consensus RecommendationBuyBuyBuyBuyBuy
Consensus Price Target$7.00$42.00$19.20$18.80$30.33
% Upside from Price Target151.80% upside32.28% upside145.84% upside130.67% upside86.55% upside
Trade Information
Market Cap$706.66 million$733.11 million$561.63 million$702.62 million$689.15 million
Beta2.14-0.210.711.880.26
Average Volume6,006,340165,1843,627,5191,023,129184,214
Sales & Book Value
Annual Revenue$2.22 million$13.80 million$42.59 million$12.52 million$17.26 million
Price / Sales318.3253.1213.1956.1239.93
CashflowN/AN/AN/AN/AN/A
Price / CashN/AN/AN/AN/AN/A
Book Value$0.50 per share$5.27 per share$0.43 per share$1.79 per share$4.07 per share
Price / Book5.566.0218.164.554.00
Profitability
Net Income$-54,810,000.00$-30,610,000.00$-18,970,000.00$-112,580,000.00$-82,370,000.00
EPS($0.46)($2.77)($0.11)($0.86)($5.15)
Trailing P/E RatioN/AN/AN/AN/AN/A
Forward P/E RatioN/AN/AN/AN/AN/A
P/E GrowthN/AN/AN/AN/AN/A
Net Margins-2,837.73%-321.26%-44.55%-321.31%-215.80%
Return on Equity (ROE)-36.69%-42.73%-23.72%-36.57%-112.72%
Return on Assets (ROA)-28.29%-28.77%-13.80%-33.53%-21.36%
Dividend
Annual PayoutN/AN/AN/AN/AN/A
Dividend YieldN/AN/AN/AN/AN/A
Three-Year Dividend GrowthN/AN/AN/AN/AN/A
Payout RatioN/AN/AN/AN/AN/A
Years of Consecutive Dividend GrowthN/AN/AN/AN/AN/A
Debt
Debt-to-Equity Ratio0.10%0.13%N/AN/AN/A
Current Ratio9.06%9.63%1.83%12.18%11.27%
Quick Ratio8.95%9.63%1.38%12.18%11.27%
Ownership Information
Institutional Ownership Percentage52.13%42.68%23.32%45.41%N/A
Insider Ownership Percentage10.50%26.30%26.10%9.00%5.90%
Miscellaneous
Employees127873395443
Shares Outstanding254.20 million23.09 million71.91 million86.21 million42.38 million
Next Earnings Date5/12/2021 (Estimated)8/4/2021 (Estimated)5/12/2021 (Confirmed)8/9/2021 (Estimated)5/10/2021 (Estimated)
OptionableOptionableNot OptionableOptionableOptionableOptionable
SourceHeadline
Financial Contrast: Chinook Therapeutics (NASDAQ:KDNY) & AC Immune (NASDAQ:ACIU)Financial Contrast: Chinook Therapeutics (NASDAQ:KDNY) & AC Immune (NASDAQ:ACIU)
americanbankingnews.com - May 8 at 11:14 AM
Chinook Therapeutics, Inc. (NASDAQ:KDNY) to Post FY2022 Earnings of ($3.64) Per Share, Cantor Fitzgerald ForecastsChinook Therapeutics, Inc. (NASDAQ:KDNY) to Post FY2022 Earnings of ($3.64) Per Share, Cantor Fitzgerald Forecasts
americanbankingnews.com - May 7 at 9:05 AM
Chinook Therapeutics Inc (KDNY)Chinook Therapeutics Inc (KDNY)
investing.com - May 1 at 8:49 AM
Chinook Therapeutics (NASDAQ:KDNY) Shares Up 7.6%Chinook Therapeutics (NASDAQ:KDNY) Shares Up 7.6%
americanbankingnews.com - April 29 at 3:58 PM
Chinook Therapeutics (NASDAQ:KDNY) Sees Large Volume IncreaseChinook Therapeutics (NASDAQ:KDNY) Sees Large Volume Increase
americanbankingnews.com - April 28 at 2:44 PM
At what point in time would I choose to purchase Chinook Therapeutics, Inc. (NASDAQ:KDNY) stock?At what point in time would I choose to purchase Chinook Therapeutics, Inc. (NASDAQ:KDNY) stock?
stocksregister.com - April 28 at 2:03 PM
Chinook Therapeutics, Inc. (NASDAQ:KDNY) Stock Forecast 2021: $40 Per Share With Bullish SignsChinook Therapeutics, Inc. (NASDAQ:KDNY) Stock Forecast 2021: $40 Per Share With Bullish Signs
marketingsentinel.com - April 27 at 9:24 AM
Cantor Fitzgerald Comments on Chinook Therapeutics, Inc.s FY2021 Earnings (NASDAQ:KDNY)Cantor Fitzgerald Comments on Chinook Therapeutics, Inc.'s FY2021 Earnings (NASDAQ:KDNY)
americanbankingnews.com - April 21 at 7:28 AM
Chinook Therapeutics (NASDAQ:KDNY) Trading 6.4% Higher Chinook Therapeutics (NASDAQ:KDNY) Trading 6.4% Higher
americanbankingnews.com - April 15 at 1:18 PM
Chinook Therapeutics, Inc. (NASDAQ:KDNY) Receives Average Recommendation of "Buy" from AnalystsChinook Therapeutics, Inc. (NASDAQ:KDNY) Receives Average Recommendation of "Buy" from Analysts
americanbankingnews.com - April 15 at 10:48 AM
Chinook Therapeutics Presents Data During the ISN World Congress of Nephrology 2021Chinook Therapeutics Presents Data During the ISN World Congress of Nephrology 2021
finance.yahoo.com - April 15 at 9:15 AM
Q1 2021 EPS Estimates for Chinook Therapeutics, Inc. (NASDAQ:KDNY) Lowered by AnalystQ1 2021 EPS Estimates for Chinook Therapeutics, Inc. (NASDAQ:KDNY) Lowered by Analyst
americanbankingnews.com - April 15 at 6:32 AM
Chinook: Q4 Earnings Snapshot | Raleigh News & ObserverChinook: Q4 Earnings Snapshot | Raleigh News & Observer
newsobserver.com - April 7 at 6:31 PM
Chinook: Q4 Earnings SnapshotChinook: Q4 Earnings Snapshot
ourmidland.com - April 7 at 6:31 PM
Chinook Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2020 Financial ResultsChinook Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2020 Financial Results
finance.yahoo.com - April 7 at 6:31 PM
Chinook Therapeutics Announces First Patient Dosed in Phase 2 AFFINITY Basket Study of ...Chinook Therapeutics Announces First Patient Dosed in Phase 2 AFFINITY Basket Study of ...
apnews.com - April 7 at 1:30 PM
Chinook Therapeutics Announces First Patient Dosed in Phase 2 AFFINITY Basket Study of Atrasentan in Proteinuric Glomerular DiseasesChinook Therapeutics Announces First Patient Dosed in Phase 2 AFFINITY Basket Study of Atrasentan in Proteinuric Glomerular Diseases
finance.yahoo.com - April 7 at 8:30 AM
Chinook Therapeutics Announces Update on Non-Renal Legacy Programs from Aduro Biotech MergerChinook Therapeutics Announces Update on Non-Renal Legacy Programs from Aduro Biotech Merger
finance.yahoo.com - April 5 at 8:35 AM
Chinook (KDNY) Surges 7%: Is This an Indication of Further Gains?Chinook (KDNY) Surges 7%: Is This an Indication of Further Gains?
finance.yahoo.com - March 31 at 2:33 PM
Chinook Therapeutics Announces Upcoming Data Presentations at ISN World Congress of Nephrology ...Chinook Therapeutics Announces Upcoming Data Presentations at ISN World Congress of Nephrology ...
apnews.com - March 30 at 6:30 PM
Chinook Therapeutics Announces Upcoming Data Presentations at ISN World Congress of Nephrology 2021 and 58th ERA-EDTA CongressChinook Therapeutics Announces Upcoming Data Presentations at ISN World Congress of Nephrology 2021 and 58th ERA-EDTA Congress
finance.yahoo.com - March 30 at 6:30 PM
Chinook Therapeutics Announces First Patient Enrolled in Pivotal Phase 3 ALIGN Study of ...Chinook Therapeutics Announces First Patient Enrolled in Pivotal Phase 3 ALIGN Study of ...
apnews.com - March 16 at 10:09 AM
Chinook Therapeutics Announces First Patient Enrolled in Pivotal Phase 3 ALIGN Study of Atrasentan for Patients with IgA NephropathyChinook Therapeutics Announces First Patient Enrolled in Pivotal Phase 3 ALIGN Study of Atrasentan for Patients with IgA Nephropathy
finance.yahoo.com - March 16 at 10:09 AM
Chinook Therapeutics, Inc. Rings the Nasdaq Stock Market Closing BellChinook Therapeutics, Inc. Rings the Nasdaq Stock Market Closing Bell
nasdaq.com - March 5 at 5:57 PM
Chinook Therapeutics and Evotec Announce Strategic Collaboration to Discover and Develop Novel ...Chinook Therapeutics and Evotec Announce Strategic Collaboration to Discover and Develop Novel ...
apnews.com - March 2 at 1:30 AM
DateCompanyBrokerageAction
2/25/2021VBI VaccinesJefferies Financial GroupInitiated Coverage
8/27/2020VBI VaccinesOppenheimerReiterated Rating
8/26/2020VBI VaccinesRaymond JamesUpgrade
6/29/2020VBI VaccinesBMO Capital MarketsReiterated Rating
3/6/2020VBI VaccinesCanaccord GenuityReiterated Rating
5/7/2021Bicycle TherapeuticsHC WainwrightBoost Price Target
5/7/2021Bicycle TherapeuticsPiper SandlerBoost Price Target
4/26/2021Bicycle TherapeuticsJMP SecuritiesInitiated Coverage
1/20/2021Bicycle TherapeuticsCantor FitzgeraldBoost Price Target
11/14/2019Bicycle TherapeuticsRoth CapitalInitiated Coverage
9/11/2019Bicycle TherapeuticsThe Goldman Sachs GroupUpgrade
6/17/2019Bicycle TherapeuticsPiper Jaffray CompaniesInitiated Coverage
12/14/2020VeruBrookline Capital ManagementBoost Price Target
3/20/2019VeruCIBCInitiated Coverage
5/5/2021ChimerixMaxim GroupInitiated Coverage
4/12/2021ChimerixJonestradingReiterated Rating
3/31/2021ChimerixWedbushInitiated Coverage
5/9/2019ChimerixCowenReiterated Rating
3/6/2019ChimerixCitigroupLower Price Target
3/22/2021Chinook TherapeuticsBloom BurtonReiterated Rating
11/2/2020Chinook TherapeuticsEvercore ISIInitiated Coverage
10/7/2020Chinook TherapeuticsSVB LeerinkInitiated Coverage
10/6/2020Chinook TherapeuticsWilliam BlairReiterated Rating
(Data available from 5/8/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.